Nov 01, 2009
By Pharmaceutical Technology Editors
Volume 21, Issue 11

News bites

EC's surprise inspections

The EC has been knocking on the doors of pharmaceutical companies to conduct surprise inspections; the agency will be looking specifically for signs of anticompetitive behaviour in the form of restrictive business practices or abuse of a dominant market position.

Read more at: http://pharmtech.com/antitrust

Improved growth forecast

After forecasting a grim fate for pharma earlier this year in terms of 2009 growth (just 2.5–3.6%), IMS has announced a happier forecast for 2010; the research firm expects the global pharma market to grow 4–6% to reach more than $825 billion.

Read more at: http://pharmtech.com/growth

Pharma's R&D trends

Earlier this year, the 2009 Edition of the CMR International Pharmaceutical R&D Factbook was released. Pharmaceutical Technology Europe spoke to the Commercial Development Manager at CMR International, Thomson Reuters, to find out some of the key trends that have been witnessed.

Read the exclusive interview at: http://pharmtech.com/reuters

The profit of counterfeits

The European Fine Chemicals Group (EFCG) has revealed some disturbing facts regarding counterfeit APIs; an estimated 20–30% of off-patent medicines in EU pharmacies are falsified at API level. At a press conference, Guy Villax, a member of the EFCG Board and CEO of Hovione (Portugal), explained that: "Falsified medicines is a business more profitable than heroin, and in most countries it is not legislated as a crime."

Read more at: http://pharmtech.com/EFCG

H1N1 vaccine approvals

The EMEA has granted marketing authorization to three vaccines against H1N1 influenza. The products concerned are Celvapan (Baxter), Pandemrix (GSK) and Forcetria (Novartis). The approvals follow the positive recommendations from the EMEA's Committee for Medicinal Products for Human Use and the EC has said that sufficient vaccines should now be available before the start of the flu season.


Back to basics for pharma

Many UK pharma companies are turning to basic business skills training to help them emerge from the recession stronger than before. In particular, pharma companies are looking to leadership skills and IT skills to keep their businesses running smoothly.

Read more at: http://pharmtech.com/basics

Space-age drug detection

Researchers at a UK University have combined crime research and spaceage technology to create a new method of detecting counterfeit pharmaceuticals. The lowcost technique detects differences in the characteristics of light reflected from printed packaging and does not require the manufacturer to undertake any special measures.

An exclusive interview regarding this technology can be read at: http://pharmtech.com/detection

Pfizer–Wyeth united

Following the completion of the $68billion acquisition of Wyeth by Pfizer, the new combined company has begun operations. Pfizer has also outlined its executive leadership team and organizational structures for commercial operations and R&D.

Read more at: http://pharmtech.com/united

lorem ipsum